• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market

    2/25/25 4:05:00 PM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FRTX alert in real time by email

    BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolution and its process for distributing cash to its stockholders. Fresh Tracks plans on filing a Certificate of Dissolution with the Delaware Secretary of State, with dissolution effective February 28, 2025.

    As previously disclosed, on January 15, 2025, the Court of Chancery of the State of Delaware appointed Albert N. Marchio II as the custodian of the Company (the "Custodian"). In connection with the dissolution, the Custodian has authorized an initial distribution of $0.96 per share to holders, as of February 28, 2025, of the Company's common stock and warrants, which were issued to investors by the Company in June 2020 and October 2020.     

    Dissolution Plan Update

    The Company is continuing to wind down its operations and resolve all outstanding liabilities. The Company currently has approximately 6.0 million outstanding shares and approximately 0.6 million outstanding eligible warrants, and the total cash to be distributed in the initial distribution is expected to be approximately $6.3 million.

    The Company expects the final winding down process to take up to ten years. During this period, the Company will maintain a reserve for expenses, both known and unknown. After the initial distribution to the stockholders, as discussed above, and the settlement of any final claims and expenses, the Company may make a second cash distribution of any remaining reserve funds to its stockholders.

    Termination of Trading on the OTC Pink Market

    Fresh Tracks' common stock is expected to cease trading on the OTC Pink Market at the close of business on February 28, 2025. This date will also serve as the date for determining stockholders and warrant holders who will be eligible to receive their pro-rata share of the distribution proceeds.

    The Company's Distribution Agent

    The Company has appointed Equiniti Trust Company, LLC ("Equiniti") as the Company's distribution agent. You may contact Equiniti with any questions about your shares, warrants and/or the distributions. Below is the contact information for Equiniti:

    Equiniti Trust Company, LLC

    48 Wall Street, 22nd Floor

    New York, NY 10005

    Attn: Shareowner Services

    Tel: (800) 937-5449

    Email: [email protected]

    Stockholders who hold shares and warrant holders who hold warrants in book entry accounts at our transfer agent, Equiniti, will receive checks in the amount of their cash distribution. Stockholders who hold shares and warrant holders who hold warrants through a broker or other DTC registered nominee will receive their cash distribution through their account at such broker or other nominee.

    Cautionary Note Regarding Forward-Looking Statements

    Any statements made in this press release relating to future financial conditions, plans, prospects, impacts, shifts, trends, progress, or strategies and other such matters, including without limitation, the planned dissolution of Fresh Tracks, the timing and amount of any distribution to stockholders and the timing of the removal of Fresh Tracks' common stock from trading on the OTC Pink Market, and similar statements, are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "might," "seek," "distribute," "dissolve," "announce," "anticipate," "believe," "estimate," "expect," "intend," "plan," "potential," and similar expressions and their variants, as they relate to Fresh Tracks, may identify forward-looking statements. Fresh Tracks cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly, and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include the timing and amount of any distributions being different than expected; the amounts that will need to be set aside as reserves by Fresh Tracks being higher than anticipated; the possible inadequacy of such reserves to satisfy Fresh Tracks' obligations; potential unknown contingencies or liabilities, and Fresh Tracks' potential inability to favorably resolve them or at all; the amount of proceeds that might be realized from the sale or other disposition of any remaining Fresh Tracks assets; the application of, and any changes in, applicable tax and other laws, regulations, administrative practices, principles and interpretations; the incurrence by Fresh Tracks of expenses relating to its dissolution being different than estimated; the Company's ability to settle, make reasonable provision for or otherwise resolve its liabilities and obligations, including the establishment of an adequate contingency reserve; and the uncertain macroeconomic and political environment. The forward-looking statements represent the estimates of Fresh Tracks as of the date hereof only. Fresh Tracks specifically disclaims any duty or obligation to update forward-looking statements.

    Fresh Tracks Therapeutics, Inc.

    Investor Contact:
     Albert N. Marchio II

    Chief Executive Officer and Chief Financial Officer

    [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/fresh-tracks-therapeutics-announces-dissolution-initial-cash-distribution-and-termination-of-trading-on-the-otc-pink-market-302385218.html

    SOURCE Fresh Tracks Therapeutics, Inc.

    Get the next $FRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FRTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

      In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

      BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company

      BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma

      6/17/24 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market

      BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolution and its process for distributing cash to its stockholders. Fresh Tracks plans on filing a Certificate of Dissolution with the Delaware Secretary of State, with dissolution effective February 28, 2025. As previously disclosed, on January 15, 2025, the Court of Chancery of the State of Delaware appointed Albert N. Marchio II as the custodian of the Company (the "Custodian"). In connection with the dissolution, the Custodian has authorized an initial distribution of $0.96 per share to holders, as of

      2/25/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

      In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

      BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Financials

    Live finance-specific insights

    See more
    • Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value Strengthened balance sheet with aggregate net proceeds of $6.6 million raised under an ATM program in March 2023 BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today

      5/10/23 4:01:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

      Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate strategic options to further develop FRTX-02 and maximize shareholder value Raised aggregate net proceeds of $6.6 million under ATM program in March 2023 BOULDER, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription the

      3/30/23 4:01:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Fresh Tracks Therapeutics Inc.

      15-12G - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/18/24 5:05:32 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Fresh Tracks Therapeutics Inc.

      10-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/15/24 4:09:01 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/7/24 8:44:19 AM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $FRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      6/11/24 9:37:53 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/31/24 5:29:19 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/23/24 5:29:14 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Fresh Tracks Therapeutics Inc.

      SC 13D - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      5/8/24 4:01:47 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

      SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      1/17/24 8:37:18 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

      SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      2/13/23 5:24:48 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      6/11/24 9:37:53 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/31/24 5:29:19 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/23/24 5:29:14 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care